1. The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial 
Daniel H. Solomon, MD, MPH, M. Elaine Husni, MD, MPH, Peter A. Libby, MD, Neville D. Yeomans, MD, A. Michael Lincoff, MD, Thomas F. Lϋscher, MD, Venu Menon, MD, Danielle M. Brennan, MS, Lisa M. Wisniewski, RN, Steven E. Nissen, MD, Jeffrey S. Borer, MD 
The American Journal of Medicine 
Volume 130, Issue 12, Pages e4 (December 2017)
DOI: /j.amjmed
Copyright © 2017 Elsevier Inc. Terms and Conditions

2. Figure 1
CONSORT diagram illustrating the participant allocation. The final population noted contributed to the intention-to-treat analysis shown in Table 1. However, in each treatment group, some patients never took a dosage of study drug and thus are not considered in the modified intention-to-treat analyses noted in Table 2.
The American Journal of Medicine  , e4DOI: ( /j.amjmed )
Copyright © 2017 Elsevier Inc. Terms and Conditions

3. Figure 2
Cumulative incidence of major toxicity in PRECISION trial. The HRs are estimated in Cox proportional hazards regression models that include aspirin use and type of arthritis. A, The primary outcome of major NSAID toxicity. B, The expanded major NSAID toxicity outcome. CI = confidence interval; BID = 2 times per day; TID = 3 times per day.
The American Journal of Medicine  , e4DOI: ( /j.amjmed )
Copyright © 2017 Elsevier Inc. Terms and Conditions

4. Figure 3
Forest plot demonstrates the risk of major NSAID toxicity by patient subgroups. CI = confidence interval; HR = hazard ratio.
The American Journal of Medicine  , e4DOI: ( /j.amjmed )
Copyright © 2017 Elsevier Inc. Terms and Conditions